Comparison
Ipamorelin vs Metformin
Side-by-side of Ipamorelin and Metformin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Metformin
Metformin for longevity: biguanide mechanism of action, TAME trial status, anti-aging dosage, weight loss data, life extension evidence in non-diabetics.
Effects at a glance
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Metformin
- •Reduces HbA1c by ~1.0 to 1.5 percentage points in type 2 diabetes; first-line agent in major guidelines
- •DPP trial: 31% reduction in T2DM incidence in adults with prediabetes over 2.8 years
- •Suppresses hepatic gluconeogenesis via AMPK activation and complex I inhibition
- •Long-term use depletes B12; annual monitoring recommended after year 2
- •Lifespan extension in non-diabetic humans is not established; TAME trial pending
- •MASTERS trial reported blunted resistance-training hypertrophy in older adults
Side-by-side
| Attribute | Ipamorelin | Metformin |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Glucophage, Fortamet, Glumetza, dimethylbiguanide |
| Half-life (hr) ↗ | 2 | 6 |
| Typical dose (mg) ↗ | 0.2 | 1500 |
| Dosing frequency | 2-3x daily | 1 to 3 times daily with meals; XR once daily |
| Routes | subcutaneous, intravenous | oral |
| Onset (hr) | 0.25 | 1 |
| Peak (hr) | 1 | 2.5 |
| Molecular weight | 711.86 | 129.16 |
| Molecular formula | C38H49N9O5 | C4H11N5 |
| Mechanism | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. | Suppresses hepatic gluconeogenesis primarily via AMPK activation and complex I inhibition; modestly improves peripheral insulin sensitivity and shifts gut microbiome composition. |
| Legal status | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA | Prescription only (FDA approved for type 2 diabetes 1994) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data; not recommended | Category B; used in gestational diabetes and PCOS per current guidance |
| CAS | 170851-70-4 | 657-24-9 |
| PubChem CID | 11338566 | 4091 |
| Wikidata | Q1666741 | Q19484 |
Safety profile
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Metformin
Common side effects
- nausea
- diarrhea
- abdominal discomfort
- metallic taste
- decreased appetite
- B12 depletion (long-term)
Contraindications
- eGFR below 30 mL/min/1.73m2
- acute or chronic metabolic acidosis
- severe hepatic impairment
- acute heart failure
- iodinated contrast within 48 hours
Interactions
- iodinated contrast media: renal injury risk; hold 48 hours peri-imaging(major)
- alcohol (heavy use): elevated lactic acidosis risk(major)
- cimetidine: raises metformin plasma levels via OCT2 inhibition(moderate)
- insulin and sulfonylureas: additive hypoglycemia risk in combination(moderate)
- dolutegravir: raises metformin exposure via OCT2(moderate)
Which Should You Take?
Metformin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is post-training recovery, pick Ipamorelin.
- → If your priority is metabolic health and glucose control, pick Metformin.
- → If your priority is healthspan extension, pick Metformin.
Edge case: If you cannot self-administer injections, Metformin is the only oral option in this pair.
Default choice: Metformin. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Ipamorelin and Metformin?
Ipamorelin and Metformin differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Ipamorelin or Metformin?
Ipamorelin half-life is 2 hours; Metformin half-life is 6 hours.
Can you stack Ipamorelin with Metformin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper